Cardiovascular disease after cancer therapy
Autor: | Conny Vrieling, Janine Nuver, E.C. Moser, Maja V. Maraldo, Thomas M. Suter, Sarah C. Darby, Berthe M.P. Aleman, Lena Specht |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2014 |
Předmět: |
medicine.medical_specialty
Pathology Cancer Research medicine.medical_treatment Alternative medicine Cancer therapy lcsh:Medicine Disease Cardiovascular lcsh:RC254-282 Article medicine Guideline development Intensive care medicine Cancer Cardiotoxicity business.industry lcsh:R lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Radiation therapy Increased risk Oncology Therapy business |
Zdroj: | European Journal of Cancer, Supplement, 12(1), 18-28 EJC Supplements, Vol 12, Iss 1, Pp 18-28 (2014) EJC Supplements |
ISSN: | 1878-1217 1359-6349 |
Popis: | Improvements in treatment and earlier diagnosis have both contributed to increased survival for many cancer patients. Unfortunately, many treatments carry a risk of late effects including cardiovascular diseases (CVDs), possibly leading to significant morbidity and mortality. In this paper we describe current knowledge of the cardiotoxicity arising from cancer treatments, outline gaps in knowledge, and indicate directions for future research and guideline development, as discussed during the 2014 Cancer Survivorship Summit organised by the European Organisation for Research and Treatment of Cancer (EORTC). Better knowledge is needed of the late effects of modern systemic treatments and of radiotherapy to critical structures of the heart, including the effect of both radiation dose and volume of the heart exposed. Research elucidating the extent to which treatments interact in causing CVD, and the mechanisms involved, as well as the extent to which treatments may increase CVD indirectly by increasing cardiovascular risk factors is also important. Systematic collection of data relating treatment details to late effects is needed, and great care is needed to obtain valid and generalisable results. Better knowledge of these cardiac effects will contribute to both primary and secondary prevention of late complications where exposure to cardiotoxic treatment is unavoidable. Also surrogate markers would help to identify patients at increased risk of cardiotoxicity. Evidence-based screening guidelines for CVD following cancer are also needed. Finally, risk prediction models should be developed to guide primary treatment choice and appropriate follow up after cancer treatment. © 2014. |
Databáze: | OpenAIRE |
Externí odkaz: |